Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE REGIMEN phase 3 trial-Reference-Cited by-同舟云学术

Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE REGIMEN phase 3 trial

Published:2024-07-15 Issue:16 Volume:137 Page:1991-1992
ISSN:0366-6999
Container-title:Chinese Medical Journal
language:en
Short-container-title:

Author:

Li Hang¹,Cheng Hao²,Lu Qianjin³,Lai Wei⁴,Tao Xiaohua⁵,Encinas Gerardo A.⁶,Vyas Shefali⁷,Wang Bo⁸,Luo Xin⁹,Li Shiqi¹⁰

Affiliation:

1. Department of Dermatology, Peking University First Hospital, National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China

2. Department of Dermatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China

3. Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China

4. Department of Dermatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China

5. Department of Dermatology, Zhejiang Provincial People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China

6. Pfizer S.A. de C.V., Mexico City, Mexico

7. Pfizer Inc., New York, NY, USA

8. Pfizer Investment Co., Ltd, Beijing 100010, China

9. Pfizer (China) R&D Co., Ltd, Shanghai 201200, China

10. Pfizer PBG, Shanghai 200041, China

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference3 articles.

1. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape;Boguniewicz;Ann Allergy Asthma Immunol,2018

2. Atopic dermatitis;Langan;Lancet,2020

3. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN phase 3 trial;Blauvelt;J Am Acad Dermatol,2022